Synairgen Future Growth

Future criteria checks 0/6

Synairgen is forecast to grow earnings at 46.6% per annum. EPS is expected to grow by 46.6% per annum.

Key information

46.6%

Earnings growth rate

46.6%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	n/a
Future return on equity	-66.9%
Analyst coverage	Low
Last updated	06 May 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BST:OMY - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	N/A	-8	-8	-8	N/A
9/30/2023	N/A	-9	-6	-6	N/A
6/30/2023	N/A	-10	-4	-4	N/A
3/31/2023	N/A	-14	-9	-9	N/A
12/31/2022	N/A	-18	-14	-14	N/A
9/30/2022	N/A	-23	-21	-21	N/A
6/30/2022	N/A	-28	-28	-28	N/A
3/31/2022	N/A	-38	-35	-35	N/A
12/31/2021	N/A	-49	-41	-41	N/A
9/30/2021	N/A	-46	-44	-44	N/A
6/30/2021	N/A	-43	-48	-48	N/A
3/31/2021	N/A	-28	-36	-36	N/A
12/31/2020	N/A	-14	-24	-24	N/A
9/30/2020	N/A	-10	-15	-15	N/A
6/30/2020	N/A	-6	-6	-6	N/A
3/31/2020	N/A	-5	-4	-4	N/A
12/31/2019	N/A	-4	-3	-3	N/A
9/30/2019	0	-4	-4	-4	N/A
6/30/2019	0	-4	-4	-4	N/A
3/31/2019	0	-3	-4	-4	N/A
12/31/2018	0	-3	-4	-4	N/A
9/30/2018	3	-1	-1	-1	N/A
6/30/2018	5	2	2	2	N/A
3/31/2018	5	2	2	2	N/A
12/31/2017	5	2	2	2	N/A
9/30/2017	3	0	N/A	-1	N/A
6/30/2017	0	-3	N/A	-3	N/A
3/31/2017	0	-3	N/A	-3	N/A
12/31/2016	N/A	-3	N/A	-3	N/A
9/30/2016	N/A	-3	N/A	-3	N/A
6/30/2016	N/A	-3	N/A	-2	N/A
3/31/2016	0	-2	N/A	-2	N/A
12/31/2015	0	-2	N/A	-2	N/A
9/30/2015	0	-2	N/A	-2	N/A
6/30/2015	0	-2	N/A	-2	N/A
3/31/2015	2	0	N/A	0	N/A
12/31/2014	4	1	N/A	2	N/A
9/30/2014	4	1	N/A	2	N/A
6/30/2014	4	1	N/A	3	N/A
3/31/2014	2	-1	N/A	0	N/A
12/31/2013	N/A	-2	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OMY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OMY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OMY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if OMY's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if OMY's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: OMY is forecast to be unprofitable in 3 years.

Synairgen Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Synairgen plc, Annual General Meeting, Oct 10, 2024

Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024

New minor risk - Financial data availability

Less than half of directors are independent

Less than half of directors are independent

Synairgen plc Announces Executive Changes

Synairgen plc Announces Board Changes

Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical Officer

Less than half of directors are independent

Less than half of directors are independent

Synairgen plc, Annual General Meeting, Jun 29, 2023

Less than half of directors are independent

Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research

Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee

Synairgen plc Announces Topline Data for Participants Treated with Sng001 in the Us National Institutes of Health (Nih)/ Aids Clinical Trials Group (Actg)-Led Activ-2 Phase 2 Adaptive Platform Trial for Covid-19

Synairgen plc Announces Changes to Its Board

Synairgen plc to Present 60 and 90-Day Long COVID Data from Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022

Synairgen Announces Positive Findings from Analysis of Lung Samples from the SG015 Trial of SNG001 in Virally Infected COPD Patients

Synairgen plc Announces Collaboration on Universal Trial

Synairgen plc, Annual General Meeting, Jun 30, 2022

Synairgen Presents Detailed Analysis of Phase 3 Sprinter Trial Evaluating Sng001 in Hospitalised Covid-19 Patients At ATS 2022

Less than half of directors are independent

Synairgen plc to Report Fiscal Year 2021 Results on May 25, 2022

Less than half of directors are independent

Synairgen plc Provides Update on SNG001 in the ACTIV-2 Phase 3 Trial for COVID-19 and on SNG001 Activity Against Delta and Omicron Variants

Less than half of directors are independent

Synairgen plc Announces Topline Results from Phase 3 SPRINTER trial of SNG001

Less than half of directors are independent

Synairgen plc Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference

Less than half of directors are independent

No independent directors

Synairgen plc Announces Results of in Vitro Studies

Synairgen Announces Data from Home Cohort of SG016 Phase II Trial of Inhaled Interferon Beta in COVID-19 Patients and Encouraging Combined Data for Whole SG016 Trial

Synairgen Announces Dosing Has Commenced with Its Inhaled Interferon Beta Product in US Government-Funded NIH ACTIV-2 Trial in COVID-19 Outpatients

New 90-day high: €2.14

New 90-day high: €2.08

Synairgen Announces Inclusion of Its Inhaled Interferon Beta Treatment in US NIH ACTIV-2 trial in COVID-19 outpatients

Synairgen plc Announces Completion of Recruitment into Its Phase Ii Home-Based Covid-19 Study of Inhaled Interferon Beta

Synairgen Announces Commencement of Dosing in Its International Phase III Study of Inhaled Interferon Beta in Hospitalised COVID-19 Patients

Synairgen plc Provides COVID-19 Clinical Programme Update

Clinigen Group plc Signs Managed Access Program Agreement with Synairgen plc

New 90-day high - €2.52

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies